CJC-1295 phase 1 human study
A 2006 trial reported that subcutaneous CJC-1295 produced sustained dose dependent increases in growth hormone and IGF-1 in healthy adults and was well tolerated.
SourceBack to search
Growth Hormone
CJC-1295 (No DAC)
CJC-1295 without DAC, also called modified GRF 1-29, is a short acting GHRH analogue that stimulates pulsatile growth hormone release. Removing the drug affinity complex shortens its action to around 30 minutes, so it is dosed alongside a ghrelin mimetic.
- Lowest cost / mg
- $2.98/mg
- at Alpha Pro Peptides
- Vendors listed
- 49
- In stock
- 68 of 73
- listings
- COA reports
- 53
Vendor listings
Compare CJC-1295 (No DAC) prices.
Show prices as
71 listings · CJC-1295 (No DAC)
In stock5mgseen 4d ago
- Alpha Pro PeptidesLowest $/mg
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock5mgseen 6d ago
In stock5mgseen 6d ago
In stock2mgseen 6d ago
In stock2mgseen 4d ago
In stock5mgseen 6d ago
In stock5mgseen 7d ago
In stock5mgseen 6d ago
In stock10mgseen 6d ago
In stock5mgseen 7d ago
In stock10mgseen 4d ago
In stock5mgseen 5d ago
In stock5mgseen 5d ago
In stock5mgseen 6d ago
In stock10mgseen 5d ago
In stock10mgseen 7d ago
In stock5mgseen 3d ago
In stock5mgseen 4d ago
Overview
What is CJC-1295 (No DAC)?
CJC-1295 without DAC, also called modified GRF 1-29, is a short acting GHRH analogue that stimulates pulsatile growth hormone release. Removing the drug affinity complex shortens its action to around 30 minutes, so it is dosed alongside a ghrelin mimetic.
- GH Support
- Recovery
- Body Composition
- Sleep Quality
What the research reports
Benefits of CJC-1295 (No DAC)
Outcomes described across the published CJC-1295 (No DAC) literature and ongoing study. Read each as research context, not a promised result.
- 01
Pulsatile GH stimulation work
Acts on the pituitary GHRH receptor to raise growth hormone while preserving the body's own pulse pattern rather than flattening it. Reported in research settings.
- 02
Pairs with ghrelin mimetics
The short acting form is usually combined with ipamorelin, where the two pathways together produce a larger pulse than either alone. Reported in research settings.
- 03
Shorter drug exposure window
Without the drug affinity complex the action lasts roughly 30 minutes, so IGF-1 does not stay elevated between doses. Described in the research record.
- 04
Dose flexibility in protocols
The brief action allows several small doses across a day, matched to waking, training and sleep rather than one sustained level. Reported in research settings.
- 05
Established GHRH mechanism
The parent molecule with DAC raised growth hormone and IGF-1 dose dependently in healthy adults in a published phase 1 programme. Reported in research settings.
Dosage and protocol
Dosage and protocol reference
Protocols use 100 to 200 mcg per injection, two or three times daily, often paired with ipamorelin across an 8 to 12 week period. Figures describe study protocols, not a personal regimen.
- Route
- Subcutaneous injection
- Example range
- 100-200 mcg
- Frequency
- Two to three times daily
- Timing
- On an empty stomach, 30 minutes before food. Common slots: waking, training, bedtime.
Clinical evidence
Clinical evidence and study base
The published record, labeled by strength so you can see what is settled and what is still emerging.
No trials of the no DAC form
No published clinical trial has tested the shorter acting no DAC version on its own. Human data comes from the DAC form and general GHRH research. Reported in the cited paper.
SourceSecretagogue IGF-1 cohort
A 2017 cohort in hypogonadal men reported raised serum IGF-1 after growth hormone secretagogue therapy, the closest human outcome data for this class. Reported in the cited paper.
SourceInteractions
How it pairs with other peptides
- Ipamorelin
- Synergistic for GH release. GHRH analogue plus ghrelin mimetic amplifies the pulse through two pathways.
- GHRP-2 peptide
- Also synergistic, though GHRP-2 adds more appetite, cortisol and prolactin effect than ipamorelin does.
- BPC-157 peptide
- No known negative interaction. Tissue repair and growth hormone release act on separate systems.
- MK-677 oral
- Stacking secretagogues raises IGF-1 and insulin resistance risk, so combined use needs lower doses.
Questions
Frequently asked questions.
What is CJC-1295 (No DAC)?
CJC-1295 (No DAC) is a peptide compound used in research settings. It is commonly studied for its role in growth hormone, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of CJC-1295 (No DAC)?
CJC-1295 (No DAC) is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does CJC-1295 (No DAC) work?
Like other research peptides, CJC-1295 (No DAC) is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is CJC-1295 (No DAC) for research use only?
Yes, products like CJC-1295 (No DAC) are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying CJC-1295 (No DAC)?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.
